Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis#Madrigal #Announces #Clinical #Data #Demonstrating #Rezdiffra #resmetirom #Significantly #Improved #Multiple #Noninvasive #Tests #Portal #Hypertension #Risk #Patients #Compensated #MASH #Cirrhosis